A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma. Issue 6 (December 2016)

• Record Type: Journal Article
• Authors: McQuade, Jennifer L.; Posada, Liberty P.; Lecagoonporn, Srisuda; Cain, Suzanne; Bassett, Roland L.; Patel, Sapna P.; Hwu, Wen-Jen; Hwu, Patrick; Davies, Michael A.; Bedikian, Agop Y.; Amaria, Rodabe N.
• Is Part Of: Melanoma research. Volume 26:Issue 6(2016)
• Publication Date: 2016-12
• Subjects: brain metastases -- melanoma -- temozolomide -- TPI 287; Melanoma -- Periodicals; Melanoma -- Periodicals; Melanomen; 616.99477
• DOI: 10.1097/CMR.0000000000000296
• Languages: English
• ISSNs: 0960-8931

Abstract

Abstract : TPI 287 is a synthetic taxane derivative with structural modifications allowing for central nervous system penetration and potential circumvention of multidrug resistance efflux pump mechanisms. The aim of this phase I study was to determine the maximum tolerated dose of the combination of TPI 287 and temozolomide in metastatic melanoma. Patients with stage IV unresectable or recurrent stage III melanoma were eligible. Stable untreated or treated brain metastases were allowed. Patients with previous taxane exposure were excluded. TPI 287 was administered intravenously on days 1, 8, and 15 and temozolomide was taken orally daily on days 1–5 of a 28-day cycle. Responses were assessed every two cycles according to WHO criteria. A total of 21 patients were enrolled. The maximum tolerated dose of the combination at this schedule was determined to be 125 mg/m 2 intravenous of TPI 287 and 110 mg/m 2 of oral temozolomide. The dose-limiting toxicity was neuropathy and six patients experienced grade III neuropathy. All patients were evaluable for tumor response. There were no complete responses; there were two partial responses and seven patients had stable disease (overall response rate 9.5% and disease control rate 42.9%). Three patients had stable disease in the brain despite progressive extracranial disease. The combination of TPI 287 and temozolomide is well tolerated in patients with metastatic melanoma, with the exception of neuropathy. The central nervous system penetration of both agents makes this a rational combination for further testing in primary and metastatic brain lesions.